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ABSTRACT 
Hepatitis-B is an infective disease predominantly affecting liver. Along with AIDS, which 
has been a major concern since 90’s. Many of the Ayurvedic herbal medicines have been 
tried and have been proved to be effective in treating Shakhashrita kamala. The objective 
of the study was to see the effect of tablet Nirocil and indigenous drugs Kashaya in 
Shakhashrita kamala (Hepatitis-B) and to compare both of them. A Total of 26 patients, 
after considering the inclusion and exclusion criteria, having signs and symptoms of 
Shakhashrita kamala were included in the study and after diagnosing Hepatitis-B by 
elevated liver function tests and HBsAg (Elisa). Patients were assessed and scores were 
given with regards to the subjective parameters like Peetata of netra, Peetata of Mootra, 
Peetata of Jihwa jala, Swethavarchas, Kandu and objective parameters like total bilirubin, 
and HBsAg. All the subjective parameters are recorded and assessed on initial day, during 
and after treatment. Objective parameters are assessed before and after treatment. Out of 
26 patients, 10 patients got completely cured, 8 patients got improvement and 8 patients 
got slight improvement. Overall assessment of the study revealed that, after treatment of 
26 patients, there were 8 patients having HBsAg positive result and 18 patients were 
having HBsAg negative result which was highly significant. Both the groups showed 
significant positive in subjective parameters. Thus study revealed that indigenous drugs 
Kashaya has significant role to play in the management of Shaksahashrita kamala. To 
conclude, the study emphasized that indigenous drugs Kashaya has significant role to play 
in the management of Shaksahashrita kamala. 
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INTRODUCTION
Acute Hepatitis-B infection is a 
generalized disease predominantly affecting 
liver. Along with AIDS, which has been a major 
concern since 90’s, Hepatitis-B is the cause of 
global health hazard in the post 2000 era. 
Because of high HBV related morbidity and 
mortality, the global disease burden of HBV is 
substantial. Despite the invention of latest drugs 
and vaccines, the infectious stage, carrier stage 
and the complications arising due to HBV has not 
been controlled up to the desired expectation[1]. 
Hence the need for alternative system of 
medicine has now been recognized worldwide. 
Hepatitis-B is claimed to be 100-200 times more 
infectious than AIDS. It is estimated that around 
2 billion people have serological evidence of past 
or present HBV infection by WHO. At the same 
time about 350 million people have been 
infected by Hepatitis-B, roughly making around 
5% of world population. In India, 34 million 
people are reactive to HBV, constituting 10% of 
entire HBV pool of the world. It is reported that 
15-40% of HBV infected patients would develop 
cirrhosis, liver failure or Hepatocellular 
carcinoma. It is also estimated that about 5-12 
lakh people die of HBV infection annually. 
Because of high HBV related morbidity and 
mortality, the global disease burden of HBV is 
substantial. Despite the invention of latest drugs 
and vaccines, the infectious stage, carrier stage 
and the complications arising due to HBV has not 
been controlled upto the desired expectation. 
Deepa C Patil et al. Effect of Certain Indigenous Drugs in Shakhashrita Kamala w.s.r to Viral Hepatitis-B 
 Available online at : http://ijapr.in Page 35 
Hence the need for alternative system of 
medicine has now been recognized world 
wide.[2] 
MATERIALS AND METHODS 
Research Design  
Total number of 26 patients excluding 
dropouts was divided into 2 groups, Group A and 
Group B, consisting of 13 patients in each group. 
The study was conducted at JSS Ayurveda college 
and Hospital. The study was conducted as a part 
of research and academic activity.  
Inclusion Criteria  
 Patients of either sex , age group between 
15-50 years 
 Patients diagnosed as Shakhashrita kamala 
[3]/ Hepatocellular jaundice, confirmed by 
serological test for HBsAg (Elisa) and Liver 
function tests were included after obtaining 
informed consent.  
Exclusion Criteria  
 HBsAg carrier (asymptomatic)  
 Hepatitis B with complications , Drug 
induced hepatitis , Alcoholic hepatitis 
 Patients with other systemic disorders were 
excluded, other variants of viral hepatitis 
were excluded. 
Diagnostic Criteria 
 With clinical features of shakhashrita 
kamala with reference to Hepatitis-B.  
 Elevated liver function test values and 
urine examinations. 
 Laboratory evidence of HBsAg by Elisa 
method. 
Investigations 
Urine -  Bile salt, Bile pigment. 
Haematological - Liver function test - HBsAg 
(Elisa Method) 
Study Design – Comparative Study  
Intervention (Plan of Treatment)  
Group A – Controlled Group  
 Amapachana by Trikatu choorna 3 gm thrice 
daily with honey and lemon juice for 3 days 
before food 
 After Mala Ranjana, Sadhyosneha by 
Haridradi Gritha, [3] according to Kostha  
 Mrudu Virechana by Trivruth lehya with 
Triphala Kwata[3], according to Kostha. 
 Shamanoushadhi by Tab Nirocil – 1 gm – 2 
thrice daily for 30 days 
Group B – Test Group 
 Amapachana by Trikatu choorna 3 gm thrice 
daily with honey and lemon juice for 3 days 
before food 
 After Mala Ranjana, Sadhyosneha by 
Haridradi Gritha, according to Kostha  
 Mrudu Virechana by Trivruth Lehya with 
Triphala Kwata, according to Kostha. 
 Shamanoushadhi by Kashaya of indigenous 
drugs 15ml with hot water before food thrice 
daily for 30 day 
Assessment Criteria 
 For the assessment of treatment, the 
following parameters were considered. They 
were graded and scores were given as follows. 
 
 
Table 1: Subjective Parameter 
Subject Scales 
Peetavarnata of Netra 
(yellowishness of eye) 
PN0 ((Nil) 
Normal 
PN1 Mild) 
Lemon Yellow 
PN2 (Moderate) 
Turmeric Yellow 
PN3 (Severe) 
Dark Yellow 
Peetavarnata of mootra 
(yellowishness of urine) 
PM0 (Nil) 
Normal 
PM1 Mild) 
Lemon Yellow 
PM2 (Moderate) 
Turmeric Yellow 
PM3 (Severe) 
Dark Yellow 
Peetavarnata of jihwa tala 
(yellowishness of tongue) 
PJ0 (Nil) 
Normal 
PJ1 Mild) 
Lemon Yellow 
PJ2 (Moderate) 
Turmeric Yellow 
PJ3 (Severe) 
Dark Yellow 
Swethavarchas(pale stool) SW0 (Present) SW1 (Absent) 
Kandu (itching) Ka0 (Present) Ka1 (Absent) 
Objective Parameters  
  Liver function test  
  HBsAg (Elisa) 
 
Overall Assessment 
Cure 
HBsAg   - Negative 
LFT value  - Normal 
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Signs & symptoms - Relieved 
completely  
Improvement  
HBsAg   - Negative 
LFT value  - nearly normal 
Signs & symptoms - Relieved 
completely  
Slight 
Improvement  
HBsAg   - Positive 
LFT value  - nearly normal to 
normal 
Signs & symptoms - Relieved 
completely  
No Improvement 
HBsAg   - Positive  
LFT values  - Unchanged 
Persistent signs and symptoms 
Assessment of the patients was made in the 
following intervals.  
For subjective parameters: From 1st day 
followed by weekly assessment.  
For Objective parameters: on 1st day and after 
45 days of administration of Shamanoushadhi. 
The data was collected and analysed the 
total score of before treatment, during treatment 
and after treatment was assessed by contingency 
co-efficient, descriptive statistics, Repeated 
measures ANOVA test. Analysis was considered 
by SPSS for windows (Statistical Presentation 
System Software) version 14.0 developed by 
SPSS, New York. 
Observation and results  
Observation 
In majority of cases, 24 patients (92.5%) 
route of transmission was unknown and 1 
patient (3.8%) transmission was by blood 
transfusion and by sexual contact. Among 26 
patients, 46.2% had chronicity between 11-20 
days, followed by 23.1% having chronicity 
between 21-30 days. All 26 patients had a 
complaint of Peetata of netra, Mootra and Jihwa 
tala. Followed by 14 patients (53.8%) having 
complaints of Kandu all over the body. 8 
patients(30.1%) had complaint of 
Swethavarchas, 7 patients(26.9%) had signs of 
enlarged liver. It is observed that 11 patients had 
a bilirubin level ranging from 10-15 mg/dl, 
followed by 5 patients having range between 0-5 
mg/dl, 4 patients having range between 15-20 
mg/dl and 2 patients having range between 35-
40 mg/dl 
Results 
Subjective Parameter 
Table 2: Showing the Results on Peetavarnata of Netra Group A 
 BT 1st 2nd 3rd 4th 5th 6th 
Nil 0 0 4 (30.8%) 8 (61.5%) 10(76.9%) 13 (100%) 13 (100%) 
Mild 2 (15.4%) 5 (38.5%) 6 (46.2%) 5 (38.5%) 3 (21.1%) 0 0 
Moderate 6 (46.2%) 6 (46.2%) 3 (23.1%) 0 0 0 0 
Severe 5 (38.5%) 2 (15.4%) 0 0 0 0 0 
Table 3: Showing the Results on Peetavarnata of Netra Group B 
 BT 1st 2nd 3rd 4th 5th 6th 
Nil 0 1 (7.7%) 1 (7.7%) 3 (23.1%) 12(92.3%) 13(100%) 13(100%) 
Mild 0 3(23.1%) 8(61.5%) 10(76.9%) 1(7.7%) 0 0 
Moderate 7(53.8%) 7(53.8%) 4(30.8%) 0 0 0 0 
Severe 6(46.2%) 2(15.4%) 0 0 0 0 0 
Group A = P value – i.e., 0.000 HS; Group B = P value – i.e., 0.000 HS 
Table 4: Showing the Results on Peetavarnata of Mootra in Group A 
 BT 1st 2nd 3rd 4th 5th 6th 
Nil 0 3(23.1%) 9(69.2%) 12(92.3%) 13(100%) 13(100%) 13(100%) 
Mild 2(15.4%) 6(46.2%) 3(23.1%) 1(7.7%) 0 0 0 
Moderate 4(30.8%) 2(15.4%) 1(7.7%) 0 0 0 0 
Severe 7(53.8%) 2(15.4%) 0 0 0 0 0 
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Table 5: Showing the Results on Peetavarnata of Mootra in Group B 
 BT 1st 2nd 3rd 4th 5th 6th 
Nil 0 1(7.7%) 10(76.9%) 13(100%) 13(100%) 13(100%) 13(100%) 
Mild 0 8(61.5%) 2(15.4%) 0 0 0 0 
Moderate 2(15.4%) 3(23.1%) 1(7.7%) 0 0 0 0 
Severe 11(84.6%) 1(7.7%) 0 0 0 0 0 
Group A = P value – i.e., 0.000 HS; Group B = P value – i.e., 0.000 HS 
Table 6: Showing the Results on Peetavarnata of Swetha varchas Group A 
 BT 1st 2nd 3rd 4th 5th 6th 
Absent 10(76.9%) 10(76.9%) 13(100%) 13(100%) 13(100%) 13(100%) 13(100%) 
Present  3(23.1%) 3(23.1%) 0 0 0 0 0 
Table 7: Showing the Results on Peetavarnata of Swetha varchas Group B 
 BT 1st 2nd 3rd 4th 5th 6th 
Absent 8(61.5%) 11(84.6%) 13(100%) 13(100%) 13(100%) 13(100%) 13(100%) 
Present 5(38.5%) 2(15.4%) 0 0 0 0 0 
Group A = P value – ie., 0.015 HS; Group B = P value – i.e., 0.001 HS 
OBJECTIVE PARAMETER 
In Group A  
There was a decrease of 11.36 mg/dl of 
total bilirubin after the treatment and which 
showed statistically significant, was a decrease 
of 411.5 iu/dl of SGOT after the treatment , there 
was a decrease of 383.81 iu/dl of SGPT after 
treatment, out of 13 patients, 6 patients were 
having HBsAg positive result and 7 patients 
were having HBsAg negative result after 
treatment. 
There was a decrease of 15.22 mg/dl of 
total bilirubin after the treatment and which 
showed highly significant result, there was a 
decrease of 701.71 iu/dl of SGOT after 
treatment, in Group B there was a decrease of 
672.11 iu/dl of SGPT values after treatment. Out 
of 13 patients 2 patients were having HBsAg 
positive result and 11 patients were having 
HBsAg negative result after treatment. The 
results showed highly significance result. 
 
Table 8: Showing the result on HBsAg in Group B 
 Pre Post 
 Positive Negative Positive Negative 
Group A 13 0 6 7 
Group B 13 0 2 11 
P values – Group A = 0.002-HS P value – Group B =0.000 – HS 
Table 9: Showing the Overall Assessment 
 Group A Group B Total 
Cured 4 (30.8%) 6 (46.2%) 10 (38.5%) 
Improvement 3 (23.1%) 5 (38.5%) 8 (30.8%) 
Slight improvement 6 (46.2%) 2 (15.4%) 8 (30.8%) 
No improvement 0 0 0 
P value = 0.235, NS  
In Group A, 4 patients got completely 
cured, 3 patients got improvement, 6 patients 
got slight improvement. In Group B, 6 patients 
got completely cured, 5 patients got 
improvement and 2 patients got slight 
improvement. 
 
 
DISCUSSION ON RESULTS 
Statistically, results showed significant 
difference between Groups A & Group B. But 
they were highly significant result within the 
groups. When comparison was done before and 
after treatment, there were few insignificant and 
statistically significant results between the 
groups. There was also a difference in overall 
improvement which was not significant 
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statistically. Group A and Group B showed 
significant results in both subjective and 
objective parameters. 
On subjective parameters 
During assessment of Peetata of Netra 
reduction was found after 5th week of treatment 
in both group A and B which showed highly 
significant results. Because the drugs used were 
hepatoprotective, and choleretic effect which 
helped in normal bilirubin metabolism. Similarly 
in assessment of Peetata of Mootra reduction 
was noted during 4h week of treatment in both 
the groups A and B. Because the drugs had 
Mutrala property significant results was 
achieved. At the same time Peetata of Jihwa tala 
showed reduction during 4th week of treatment. 
Swethavarchas showed a decrease during 2nd 
week of treatment in both groups A and B. Due 
to the action of the Dravyas, obstruction was 
relieved and highly significant results were 
observed.  
On Objective Parameters 
The levels of total bilirubin, SGOT and 
SGPT showing raised values changed to border 
line to normal levels after the study period of 45 
days. The result indicated highly significant P 
value < 0.001 was observed within the groups. 
But N P> 0.005 changes was observed in 
between the groups. The results of HBsAg, group 
B showed highly significant result compared to 
group A. The reason of which can be positively 
interpreted that Group B had a combination of 5 
indigenous drugs where as in Group A it was a 
single drug. So positive result was observed and 
also all the indigenous drugs were having 
antiviral and immunomodulator activity which 
helped in fast relief of signs and symptoms and 
even LFT values. Overall a highly significant 
result was observed because of the multi action 
of the indigenous drugs on hepatic cells. In 
persistent positive cases a total of 
30.1%remained seropositive for HBsAg even 
after the completion of 45 days of treatment. 
Only for these patients medicines were 
continued even after the treatment period, out of 
which 26.9% became seronegative within 15-30 
days. 
Criteria for Selection of Indigenous Drug 
Kwath 
The ingredients are Daruharidra, Katuki, 
Kasani, Erandas, Rohitaka, Sharapunkha[4],[5],[6] 
These drugs were selected on the basis of their 
indication in kamala and Yakrit vikara.[3],[4] The 
majority of drugs have properties of Shothahara, 
Yakrith uttejaka hepatoprotective, 
immunomodular, and hepatic cell 
regenerator.[3],[7] However, the drugs were tried 
once on laboratory animals. At the same time it 
was found out that these drugs are 
hepatoprotective in general but not specifically 
on Hepatitis-B. Majority of these 6 drugs were 
formulations advised in Kamala.[3],[6] Hence, 
keeping all these points in mind, this study is 
undertaken to evaluate the efficacy of 6 drugs in 
combination. 
CONCLUSION 
Many of the Ayurvedic herbal medicines 
have been tried and have been proved to be 
effective in treating Shakhashrita kamala. Still 
there was no effective and specific medicine for 
treating Hepatitis-B. The objective of the study 
was to see the effect of tablet Nirocil and 
indigenous drugs Kashaya in Shakhashrita 
kamala viz., Hepatitis-B, and to compare both of 
them. Total of 26 patients, after considering the 
inclusion and exclusion criteria, having signs and 
symptoms of Shakhashrita kamala viz., Hepatitis-
B were included in the study and after 
diagnosing Hepatitis-B by elevated liver function 
test and HBsAg (Elisa). Patients were assessed 
and scores were given with regards to the 
subjective parameters like Peetata of Netra, 
Peetata of Mootra, Peetata of Jihwa jala, 
Swethavarchas, Kandu. Objective parameters like 
total bilirubin, SGOT, SGPT and HBsAg. All these 
subjective parameters were recorded and 
assessed on initial day, during and after 
treatment. objective parameters are assessed 
before and after treatment. Overall assessment 
showed symptomatic cure and improvement in 
most of the cases of both the groups. Out of 26 
patients, 38.5% got completely cured and 30.8% 
got improvement and 30.8% got slight 
improvement. Both the groups showed 
significant result in subjective parameters. 
Group B showed highly significant result in sero 
conversion of HBsAg when compared to group A. 
There was no difference in the results between 
two groups. In comparison, general observation 
and individual results of indigenous drugs 
Kashaya proved it to be more beneficial in 
reducing the symptoms and in sero conversion 
of HBsAg. A elaborative scrutiny is needed in 
finding out HBsAg positively in patients coming 
with symptoms of jaundice / hepato cellular. 
Laboratory investigations played a major role in 
diagnosing and treating the disease with clinical 
findings playing a secondary role. The probable 
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mode of action of indigenous drugs can be 
inferred as hepatoprotective, immunomodulator, 
choleretic effect and antiviral agent. In the 
present study patients of group B showed a 
highly significant results compared to group A. 
Thus Kashaya prepared out of indigenous drugs 
proved to be beneficial. Thus study revealed that 
indigenous drugs Kashaya has significant role to 
play in the management of Shaksahashrita 
kamala viz Viral Hepatitis-B. 
 REFERENCES 
1. Gastrointestinal and Liver Disease, by 
Sleisenger and Fordtran’s, 7th Edition 2003, 
Vol. II, Chap. 68, Viral Hepatitis , published 
by Saunders, New York. Pp.1285-1303 
2. Harrison’s Principles of Internal Medicine, 
edited by Antony S. Fauci, et al., published by 
Mc. Graw Hill,15th Edition, Vol II, 1998 : 
Pp.1660-1725 
3. Charaka, In Pandu Chikitsa Adhyaya - Chikitsa 
Sthana. Agnivesha, Charaka samhita, 
Ayurveda Dipika commentary of 
Chakrapanidatta, Jalpakalpataru 
commentary of Gangadhara, ed. By Kaviraja 
shree Narendranatha Sen Gupta and Kaviraj 
Shree Balichandra Sen Gupta, Published by 
Chowkambha Orientalia, Varanasi, reprint 
1991, part 3, Part 4. Pp.1321-1335 
4. Dhanvantri Nighantu, edited by Prof. 
Priyavat Sharma, translated by Dr.Guru 
Prasad Sharma, II Edition, published by 
Chaukambha Orientalia, Varanasi, 1998: 
Pp.23,26,34. 
5. Bhavamishra, In Bhavaprakash Vidyothini 
Hindi Commentary of Sri Bhavamisra, by 
Pandi Sri. Bhrama Shankara Mishra, Part II, 
9th Edition, published by Chaukambha 
Orientalia, Varanasi, 1999 : Pp.107-109 
6. Dravyaguna Vijnana, edited by Prof. P.V. 
Sharma, Vol. II, 16th Edition, published by 
Chaukambha Orientalia, Varanasi, 1995: 
Pp.58,441,537,548,552,554. 
7. Indian Materia Medica, ed. by K.M. 
Nadakarni, forwarded by R.N. Chopra, pub. 
Bombay Publication, 3rd Edition,VOL-1 2 3 4. 
1976. Pp.44,302,557,699,878,1841. 
 
 
Cite this article as:  
Deepa C Patil, Veena G Rao, Shashidhar HB. A Controlled Clinical 
Study on the Effect of Certain Indigenous Drugs in Shakhashrita 
Kamala with Special Reference to Viral Hepatitis-B. Int. J. Ayur. 
Pharma Research. 2014;2(8):33-39. 
Source of support: Nil, Conflict of interest: None Declared 
 
*Address for correspondence 
Dr. Deepa C Patil 
Reader 
Dept. of Kayachikitsa 
JSS Ayurvedic College 
Lalithadripura Road, Alanahalli 
Mysore-570031, Karnataka 
India. 
Ph: +919886485005 
Email: deepsmysore@gmail.com 
